Deceased patients
| Sex . | LAD . | Age, mo . | Source, HLA-matching . | Donor . | CMV patient/donor . | Conditioning . | Serotherapy . | GVHD prophylaxis . | Engraftment, d . | GF, mo . | aGVHD . | 2nd allo-HSCT . | Cause of death, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | I | 11 | BM, 10/10 | MSD | −/+ | Treo + Flu | ATG | CSA | Yes, +27 | No | Grade 0 | No | Infection, +1 |
| M | I | 23 | BM, 10/10 | MUD | +/− | Bu + Cy | ATG | CSA + corticosteroids | Yes, +49 | SGF, +2 | Grade I | SGF, +4 | Infection, +26 |
| F | I | 3 | BM, 10/10 | MFD | n.a. | Treo + Flu + TT | ATG | CSA + MMF | No | PGF, +0.3 | No | No | Infection, +0.3 |
| M | III | 25 | CB, <5/6 | MMUD | +/+ | Bu + Flu | ATG | CSA + MMF | No | PGF, +0.7 | No | PGF | Infection, +4 |
| F | 12 | CB, <5/6 | MMUD | +/− | Bu + Flu | ATG | CSA + corticosteroids | Yes, +15 | No | Grade II | No | Infection, +8 | |
| F | I | 30 | BM | MSD | −/+ | Bu + Cy | None | CSA + MTX | Yes, +12 | No | Grade III | No | septic shock, +10 |
| F | I | 77 | PB, 9/10 | MUD | +/− | Bu + Flu | ATG | CSA + MTX | Yes, +14 | No | Grade IV | No | GVHD, +3 |
| M | I | 137 | PB, 10/10 | MUD | n.a. | Bu + Flu + Cy | ATG | Other | Yes, +15 | No | Grade IV | No | GVHD, +3 |
| M | I | 20 | PB, 9/10 | MUD | n.a. | Mel + Flu | Alemtuzumab | CSA+MMF | Yes, +61 | No | Grade IV | No | GVHD, +3 |
| M | III | 15 | CB, 5/6 | MMUD | +/− | Bu + Flu | ATG | CSA+corticosteroids | Yes, +35 | No | Grade II | No | cGVHD, +13 |
| F | I | 5 | BM | n.a. | −/+ | Mel + Flu | ATG | CSA | Yes, +26 | No | Grade III | No | GVHD, +9 |
| F | I | 47 | PB | n.a. | n.a. | Mel + Flu | ATG | CSA + MTX | Yes, +19 | No | Grade IV | No | GVHD, +2 |
| M | I | 6 | CB, 5/6 | MMUD | −/− | Bu + Cy | ATG | n.a. | Yes, +19 | No | Grade I | No | Accident, +9 |
| Sex . | LAD . | Age, mo . | Source, HLA-matching . | Donor . | CMV patient/donor . | Conditioning . | Serotherapy . | GVHD prophylaxis . | Engraftment, d . | GF, mo . | aGVHD . | 2nd allo-HSCT . | Cause of death, mo . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | I | 11 | BM, 10/10 | MSD | −/+ | Treo + Flu | ATG | CSA | Yes, +27 | No | Grade 0 | No | Infection, +1 |
| M | I | 23 | BM, 10/10 | MUD | +/− | Bu + Cy | ATG | CSA + corticosteroids | Yes, +49 | SGF, +2 | Grade I | SGF, +4 | Infection, +26 |
| F | I | 3 | BM, 10/10 | MFD | n.a. | Treo + Flu + TT | ATG | CSA + MMF | No | PGF, +0.3 | No | No | Infection, +0.3 |
| M | III | 25 | CB, <5/6 | MMUD | +/+ | Bu + Flu | ATG | CSA + MMF | No | PGF, +0.7 | No | PGF | Infection, +4 |
| F | 12 | CB, <5/6 | MMUD | +/− | Bu + Flu | ATG | CSA + corticosteroids | Yes, +15 | No | Grade II | No | Infection, +8 | |
| F | I | 30 | BM | MSD | −/+ | Bu + Cy | None | CSA + MTX | Yes, +12 | No | Grade III | No | septic shock, +10 |
| F | I | 77 | PB, 9/10 | MUD | +/− | Bu + Flu | ATG | CSA + MTX | Yes, +14 | No | Grade IV | No | GVHD, +3 |
| M | I | 137 | PB, 10/10 | MUD | n.a. | Bu + Flu + Cy | ATG | Other | Yes, +15 | No | Grade IV | No | GVHD, +3 |
| M | I | 20 | PB, 9/10 | MUD | n.a. | Mel + Flu | Alemtuzumab | CSA+MMF | Yes, +61 | No | Grade IV | No | GVHD, +3 |
| M | III | 15 | CB, 5/6 | MMUD | +/− | Bu + Flu | ATG | CSA+corticosteroids | Yes, +35 | No | Grade II | No | cGVHD, +13 |
| F | I | 5 | BM | n.a. | −/+ | Mel + Flu | ATG | CSA | Yes, +26 | No | Grade III | No | GVHD, +9 |
| F | I | 47 | PB | n.a. | n.a. | Mel + Flu | ATG | CSA + MTX | Yes, +19 | No | Grade IV | No | GVHD, +2 |
| M | I | 6 | CB, 5/6 | MMUD | −/− | Bu + Cy | ATG | n.a. | Yes, +19 | No | Grade I | No | Accident, +9 |
cGVHD, chronic GVHD; F, female; M, male; n.a., data not available.